Prevention of posterior capsular opacification through cyclooxygenase-2 inhibition

Molecular Vision

Volumn 13, Issue , 2007, Pages 677-691

  Chandler, Heather L ^a   Barden, Curtis A ^a   Lu, Ping ^a   Kusewitt, Donna F ^a   Colitz, Carmen M H ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LUMICAN; MESSENGER RNA; PROSTAGLANDIN E2; ROFECOXIB; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPSULOTOMY; CATARACT; CATARACT EXTRACTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; EX VIVO STUDY; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; LENS EPITHELIUM; MESENCHYME CELL; NONHUMAN; OPHTHALMOLOGY; PHACOEMULSIFICATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VETERINARY MEDICINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CATARACT; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOG DISEASES; DOGS; EPITHELIAL CELLS; LACTONES; LENS, CRYSTALLINE; MESODERM; PYRAZOLES; SULFONAMIDES; SULFONES; UP-REGULATION;

EID: 34248147055     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Francis PJ, Berry V, Moore AT, Bhattacharya S. Lens biology: development and human cataractogenesis. Trends Genet 1999; 15:191-6.
2. Davidson MG, Nelms SR. Diseases of the lens and cataract formation. In: Gelatt KN, editor. Veterinary Ophthalmology. 3rd ed. Philadelphia: Lippincott/Williams & Wilkins; 1999. p. 797-825.
3. Beebe DC. The Lens. In: Kaufman PL, Alm A, editors. Adler's physiology of the eye: clinical application. 10th ed. St. Louis: Mosby; 2003. p. 117-58.
4. Apple DJ, Rabb MF. Lens and pathology of intraocular lenses. In: Apple DJ, Rabb MF, editors. Ocular Pathology: clinical applications and self-assessment, 5th ed. St. Louis: Mosby; 1998. p. 117-204.
5. Medvedovic M, Tomlinson CR, Call MK, Grogg M, Tsonis PA. Gene expression and discovery during lens regeneration in mouse: regulation of epithelial to mesenchymal transition and lens differentiation. Mol Vis 2006; 12:422-40.
6. de Iongh RU, Wederell E, Lovicu FJ, McAvoy JW. Transforming growth factor-beta-induced epithelial-mesenchymal transition in the lens: a model for cataract formation. Cells Tissues Organs 2005; 179:43-55.
7. Saika S, Ikeda K, Yamanaka O, Sato M, Muragaki Y, Ohnishi Y, Ooshima A, Nakajima Y, Namikawa K, Kiyama H, Flanders KC, Roberts AB. Transient adenoviral gene transfer of Smad7 prevents injury-induced epithelial-mesenchymal transition of lens epithelium in mice. Lab Invest 2004; 84:1259-70.
8. Lu S, Yu G, Zhu Y, Archer MC. Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation. Int J Cancer 2005; 116:847-52.
9. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17:548-58.
10. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 23:912-23.
11. McDonnell PJ, Zarbin MA, Green WR. Posterior capsule opacification in pseudophakic eyes. Ophthalmology 1983; 90:1548-53.
12. Apple DJ, Solomon KD, Tetz MR, Assia EI, Holland EY, Legler UF, Tsai JC, Castaneda VE, Hoggatt JP, Kostick AM. Posterior capsule opacification. Surv Ophthalmol 1992; 37:73-116.
13. Sinskey RM, Cain W Jr. The posterior capsule and phacoemulsification. J Am Intraocul Implant Soc 1978; 4:206-7.
14. Wilhelmus KR, Emery JM. Posterior capsule opacification following phacoemulsification. Ophthalmic Surg 1980; 11:264-7.
15. Binkhorst CD, Gobin MH. Injuries to the eye with lens opacity in young children. Ophthalmologica 1964; 148:169-83.
16. Hiles DA, Wallar PH. Phacoemulsification versus aspiration in infantile cataract surgery. Ophthalmic Surg 1974; 5:13-6.
17. Bras ID, Colitz CM, Saville WJ, Gemensky-Metzler AJ, Wilkie DA. Posterior capsular opacification in diabetic and nondiabetic canine patients following cataract surgery. Vet Ophthalmol 2006; 9:317-27.
18. Wormstone IM. Posterior capsule opacification: a cell biological perspective. Exp Eye Res 2002; 74:337-47.
19. Nishi O. Posterior capsule opacification. Part 1: Experimental investigations. J Cataract Refract Surg 1999; 25:106-17.
20. Biswas NR, Mongre PK, Das GK, Sen S, Angra SK, Vajpayee RB. Animal study on the effects of catalin on aftercataract and posterior capsule opacification. Ophthalmic Res 1999; 31:140-2.
21. Cortina P, Gomez-Lechon MJ, Navea A, Menezo JL, Terencio MC, Diaz-Llopis M. Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture. Graefes Arch Clin Exp Ophthalmol 1997; 235:180-5.
22. Seki T, Yabe N, Kawashima C. Long-term efficacy of diclofenac sodium after PEA and IOL surgery. Folia Ophthalmology Japan 1992; 43:1452-1456.
23. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19:19-27.
24. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999; 18:7908-16.
25. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063-73.
26. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 2002; 42:55-80.
27. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94:252-66.
28. Tan HN, Liu Y, Diao HL, Yang ZM. Cyclooxygenases and prostaglandin E synthases in preimplantation mouse embryos. Zygote 2005; 13:103-8.
29. Cha YI, Solnica-Krezel L, DuBois RN. Fishing for prostanoids: deciphering the developmental functions of cyclooxygenase-derived prostaglandins. Dev Biol 2006; 289:263-72.
30. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38:97-120.
31. Verburg KM, Maziasz TJ, Weiner E, Loose L, Geis GS, Isakson PC. Cox-2-specific inhibitors: definition of a new therapeutic concept. Am J Ther 2001; 8:49-64.
32. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006; 94:346-50.
33. Dai Y, Wang WH. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol 2006; 12:2884-9.
34. Marks F, Furstenberger G, Neufang G, Muller-Decker K. Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs. Recent Results Cancer Res 2003; 163:46-57; discussion264-6.
35. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99:2254-9.
36. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277:27613-21.
37. Zhang GS, Liu DS, Dai CW, Li RJ. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol 2006; 81:242-55.
38. Michael MS, Badr MZ, Badawi AF. Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells. Int J Mol Med 2003; 11:733-6.
39. Colitz CM, Davidson MG, McGAHAN MC. Telomerase activity in lens epithelial cells of normal and cataractous lenses. Exp Eye Res 1999; 69:641-9.
40. Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 2003; 339:62-6.
41. McDonnell PJ, Rowen SL, Glaser BM, Sato M. Posterior capsule opacification. An in vitro model. Arch Ophthalmol 1985; 103:1378-81.
42. Kappelhof JP, Vrensen GF. The pathology of after-cataract. A minireview. Acta Ophthalmol Suppl 1992; 205:13-24.
43. Davidson MG, Wormstone M, Morgan D, Malakof R, Allen J, McGahan MC. Ex vivo canine lens capsular sac explants. Graefes Arch Clin Exp Ophthalmol 2000; 238:708-14.
44. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/ beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993; 120:757-66.
45. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83.
46. Boyd D. Invasion and metastasis. Cancer Metastasis Rev 1996; 15:77-89.
47. Wormstone IM, Tamiya S, Anderson I, Duncan G. TGF-beta2-induced matrix modification and cell transdifferentiation in the human lens capsular bag. Invest Ophthalmol Vis Sci 2002; 43:2301-8.
48. Maidment JM, Duncan G, Tamiya S, Collison DJ, Wang L, Wormstone IM. Regional differences in tyrosine kinase receptor signaling components determine differential growth patterns in the human lens. Invest Ophthalmol Vis Sci 2004; 45:1427-35.
49. Gordon-Thomson C, de Iongh RU, Hales AM, Chamberlain CG, McAvoy JW. Differential cataractogenic potency of TGF-beta1, -beta2, and -beta3 and their expression in the postnatal rat eye. Invest Ophthalmol Vis Sci 1998; 39:1399-409.
50. Lee EH, Joo CK. Role of transforming growth factor-beta in transdifferentiation and fibrosis of lens epithelial cells. Invest Ophthalmol Vis Sci 1999; 40:2025-32.
51. Hales AM, Chamberlain CG, Murphy CR, McAvoy JW. Estrogen protects lenses against cataract induced by transforming growth factor-beta (TGFbeta). J Exp Med 1997; 185:273-80.
52. Majima K, Kojima Y, Ouhashi F. Cell biological analysis with respect to cause of fibrous opacification of the anterior capsule after cataract extraction. Ophthalmologica 1998; 212:364-8.
53. Pandey SK, Cochener B, Apple DJ, Colin J, Werner L, Bougaran R, Trivedi RH, Macky TA, Izak AM. Intracapsular ring sustained 5-fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study. J Cataract Refract Surg 2002; 28:139-48.
54. Zaturinsky B, Naveh N, Saks D, Solomon AS. Prevention of posterior capsular opacification by cryolysis and the use of heparinized irrigating solution during extracapsular lens extraction in rabbits. Ophthalmic Surg 1990; 21:431-4.
55. Steinberg EP, Javitt JC, Sharkey PD, Zuckerman A, Legro MW, Anderson GF, Bass EB, O'Day D. The content and cost of cataract surgery. Arch Ophthalmol 1993; 111:1041-9.
56. Ellwein LB, Urato CJ. Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 2002; 120:804-11.
57. Moisseiev J, Bartov E, Schochat A, Blumenthal M. Long-term study of the prevalence of capsular opacification following extracapsular cataract extraction. J Cataract Refract Surg 1989; 15:531-3.
58. Takeda K, Kanekura T, Kanzaki T. Negative feedback regulation of phosphatidylinositol 3-kinase/Akt pathway by over-expressed cyclooxygenase-2 in human epidermal cancer cells. J Dermatol 2004; 31:516-23.
59. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 2003; 38:49-58.
60. Vanderveen EE, Grekin RC, Swanson NA, Kragballe K. Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch Dermatol 1986; 122:407-12.
61. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83:493-501.
62. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003; 278:35451-7.
63. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003; 24:985-90.
64. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004; 64:1444-51.
65. Ebert AD, Bartley J, David M. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions - old answers? Eur J Obstet Gynecol Reprod Biol 2005; 122:144-50.
66. Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update 2006; 12:49-56.
67. Colitz CMH, Chandler HL, Lu P, Sugimoto Y, Barden CA, Metzler ALG, Wilkie DA, Bras ID, Kuonen VJ, Robbin TE. Estrogen Localization and Local Synthesis of Estrogen by Cataractous LEC. ARVO Annual Meeting; 2005 May 1-5; Fort Lauderdale(FL).
68. Marshall JL, Stanfield KM, Silverman L, Khan KN. Enhanced expression of cyclooxygenase-2 in glaucomatous dog eyes. Vet Ophthalmol 2004; 7:59-62.
69. Sellers RS, Silverman L, Khan KN. Cyclooxygenase-2 expression in the cornea of dogs with keratitis. Vet Pathol 2004; 41:116-21.
70. Cullen CL, Sims DE, Singh A, McMarville C, Wilcock BP, Simmons DL. Cyclooxygenase-1, -2, and -3 expression in clinically normal and glaucomatous canine eyes. Veterinary Ophthalmology 2004; 7:441.